Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I wonder if she took her "Carpet Bag" with her?
alltheway, I agree WDCO dumping for the past few weeks, hopefully their done. Long hold anyway may pick some more around these levels "technicals look good for reversal" jmho.
any opinions on playing thanksgiving week? The past few years I usually stayed out due to low volume, don't want to get stuck in any Turkey's!.. lol
PANL, hot today glad I held.eom
noticed the yahoo poster didn't say the directors bought them back at an .08 option either.
Buzz pinksheets have them listed.
http://www.pinksheets.com/quote/news.jsp?symbol=AAC
Well here'S Another fund scamming,
50m fine I wonder how much they made..lol
SEC Charges Morgan Stanley With Inadequate
Disclosure in Mutual Fund Sales
Morgan Stanley Pays $50 Million To Settle SEC Action
FOR IMMEDIATE RELEASE
2003-159
Washington, D.C., Nov. 17, 2003 ? The Securities and Exchange Commission today announced the institution and simultaneous settlement of an enforcement action against Morgan Stanley DW Inc. (Morgan Stanley) for failing to provide customers important information relating to their purchases of mutual fund shares. As part of the settlement, Morgan Stanley will pay $50 million in disgorgement and penalties, all of which will be placed in a Fair Fund for distribution to certain Morgan Stanley customers.
Stemming from the SEC's ongoing industry-wide investigation of mutual fund sales practices, this inquiry uncovered two distinct, firm-wide disclosure failures by Morgan Stanley. The first relates to Morgan Stanley's "Partners Program" and its predecessor, in which a select group of mutual fund complexes paid Morgan Stanley substantial fees for preferred marketing of their funds. To incentivize its sales force to recommend the purchase of shares in these "preferred" funds, Morgan Stanley paid increased compensation to individual registered representatives and branch managers on sales of those funds' shares. The fund complexes paid these fees in cash or in the form of portfolio brokerage commissions.
Morgan Stanley also failed to adequately disclose at the point of sale the higher fees associated with large ($100,000 or greater) purchases of Class B shares of certain of its proprietary mutual funds. In connection with its recommendation to customers to purchase certain Class B shares, Morgan Stanley did not adequately inform customers at the point of sale that large purchases of such shares were subject to higher fees. Significantly, Morgan Stanley also failed to explain to customers that those fees could have a negative impact on customers' investment returns. As with the sales of funds in the "preferred" programs, Morgan Stanley's sales force stood to earn more on sales of Class B shares of its proprietary funds than on sales of Class A shares.
The Commission's Order finds that this conduct violated Section 17(a)(2) of the Securities Act of 1933 and Rule 10b-10 under the Securities Exchange Act of 1934. Section 17(a)(2) prohibits the making of materially misleading statements or omissions in the offer and sale of securities. Rule 10b-10 requires broker dealers to disclose the source and amount of any remuneration received from third parties in connection with a securities transaction. The Order also finds that the conduct violated NASD Rule 2830(k), which prohibits NASD members from favoring the sale of mutual fund shares based on the receipt of brokerage commissions.
Stephen M. Cutler, Director of the Commission's Division of Enforcement, said: "Unbeknownst to Morgan Stanley's customers, Morgan Stanley received monetary incentives -- in the form of "shelf space" payments -- to sell particular mutual funds to its customers. When customers purchase mutual funds, they should understand the nature and extent of any conflicts of interest that may affect the transaction."
Morgan Stanley has agreed to settle this matter, without admitting or denying the findings in the Commission's Order. As part of the settlement, Morgan Stanley will pay $25 million in disgorgement and prejudgment interest. In addition, Morgan Stanley will pay civil penalties totaling $25 million. The entire $50 million payment will be placed in a Fair Fund for distribution to customers who purchased "preferred" fund shares from January 1, 2000 through the present.
In addition, Morgan Stanley has undertaken to, among other things, (1) place on its website disclosures regarding the Partners Program; (2) provide customers with a disclosure document that will disclose, among other things, specific information concerning the Partners Program, and the differences in fees and expenses connected with the purchase of different mutual fund share classes; (3) for those customers that bought certain Class B shares in amounts of $100,000 or more, offer to convert those customers' Class B shares to A shares; (4) retain an independent consultant to conduct a review of, and to provide recommendations concerning, Morgan Stanley's disclosures, policies and procedures and its plan to offer to convert Class B shares to A shares; and (5) adopt the recommendations of the independent consultant.
Finally, the Commission's Order censures Morgan Stanley and orders it to cease-and-desist from committing or causing any violations of Section 17(a)(2) of the Securities Act of 1933 and Rule 10b-10 under the Securities Exchange Act of 1934.
"Morgan Stanley's firm-wide failure to adequately disclose to customers at the point of sale the greater costs associated with large purchases of certain B shares and the potential greater returns associated with A shares made the brokers better off and their customers worse off," said Arthur S. Gabinet, District Administrator of the Commission's Philadelphia District Office. "Brokerage firms have a duty to ensure that the information they give their customers about different classes of mutual fund shares is complete and accurate, and that their recommendations are made for the benefit of customers, not themselves."
The NASD also announced today a settled action against Morgan Stanley for violations of NASD Rule 2830(k) arising from the Partners Program and its predecessor.
AAC form 4 doesnt look bad, good (TAX) move in my opinion.
boy, I feel better I'm in that fund!lol...
Re;correction (INSS) eom.
Buzz I like the chart, looks like a possible bottom.
ISNN also has a similar pattern. both on watch, thanks
http://stockcharts.com/def/servlet/SC.web?c=inss,uu[m,a]daclyiay[dc][pb50!b200][vc60][iLb14!La12,26,...
Buzz, would that be called the "E" effect.lol
EEC, I agree, ouch! eom.
Alltheway, I agree the mm's are really controlling this well especially WDCO (waaadco lol) maybe paying off the debt
2 1/2 million$/17m shares = .14 (rough numbers)
Could it be that simple? who knows. JMHO
November 13, 2003 02:40 PM US Eastern Timezone
NanoSignal Corp. -- Formerly MicroSignal -- Joint Venture for Capital Raise
LAS VEGAS--(BUSINESS WIRE)--Nov. 13, 2003--NanoSignal Corp. (OTCBB: MSGL) is pleased to announce that its investment banker, Ravinia Capital, LLC, is currently in discussions with several investment banking firms for joint venturing on a $6,000,000 capital raise for the company. In addition to this process, Ravinia is also reviewing and negotiating on several proposals. The proposals being reviewed are to establish up to $25,000,000 leasing and financing facility for the purchase/lease of SLICES Technology.
This press release contains "forward-looking statements" within the meaning of Private Securities Litigation Reform Act of 1995. Such statements can be identified by lead-in "Looking Forward." These statements are not guarantees of future performance and involve significant risks and uncertainties. Actual results may vary materially from those in the forward-looking statements as a result of the effectiveness of management's strategies and decisions, general economic and business conditions, new or modified statutory or regulatory requirements, and changing price and market conditions. No assurance can be given that these are all the factors that could cause actual results to vary materially from the forward-looking statement. Risks and uncertainties of the company will be detailed from time to time in the company's periodic reports to be filed with the Securities and Exchange Commission.
Rawnoc is in Rahhnoc mode. lol
I'm From Florence,bout 30 min away. Small world eom.
thanks. eom
Evo, your opinion on BOCX good entry point?eom.
CNV you can say that again. eom
ps. My "Buzzfolio" is Green too! LOL Thanks Buzz.
Camel, I will also add FOTO to my "Rawfolio" hopefully on monday to many running today to zone in, I need another set of hands.
I'm back in TSBB too. sold on the last run and the mm's filled below ask. cant complain about that
camel, nice flip.missed it oem.
Thanks buzz, I was scared there for a minute I thought raw was drinking some beer leftover from the 70's. LOL.
Buzz, I agree 100% got too hectic.eom
well the call he made when it was a penny stock makes up for that many times, I wont forget that one and like an idiot I sold around 6-7$ oh well live and learn.
thanks buzz.
Raw, how far off was your call?eom
billyjam, I'm only holding about 1200 lbs.lol
Alltheway, what did you think of todays pr, I took it as both good and bad. less debt more dilution. Still look pretty good though.
yep, back in @.155 for a long hold. eom
Alltheway, I hope so. sold most of my position in the .20's time to load up again.
thats what I thought, thanks eom
Omni Question,
maybe a stupid question but,
is the float size irrelevant in a breakout trade?
Chipped well said, have a great weekend. eom
In GMXX on news:
GeneMax Corp.'s 'TAP' Cancer Therapy Featured on ABC News 'BusinessNOW' Program, Sunday Nov. 2, 2003
BLAINE, Wash., Oct. 30 /PRNewswire-FirstCall/ -- GeneMax Corp.
(OTC Bulletin Board: GMXX; Frankfurt: GX1) and its Patented TAP cancer therapy
will be featured in a new segment in an upcoming broadcast on the ABC News
Program "BusinessNOW" on Sunday, November 2, 2003.
The TV segment focuses on GeneMax's TAP cancer therapy moving toward human
trials and features recent interviews with Chairman & CSO,
Dr. Wilfred Jefferies and company President & CEO, Ronald Handford.
BusinessNOW airs weekly on ABC Television stations in New York and
Raleigh, North Carolina, as well as on the cable television network, TECH TV.
The program is a half hour business news magazine that covers today's leading
trends in business in an entertaining format that takes viewers on location.
Viewers can watch the program live as follows:
-- Nov. 9, 2003: WABC (New York) Channel 7 @ 10:30 a.m. EST
-- Nov. 9, 2003: Tech TV (National Cable) @ 2:00 p.m. EST
The segment will also be available for viewing via streaming video on the
ABCNews.com website after 6:00 p.m. EST on November 1, 2003 at
http://abcnews.go.com/sections/business/BusinessNow/BusinessNow.html .
The program will also be distributed to approximately 150 of ABC's
affiliates for airing at a later date.
About GeneMax Corp.: GeneMax Corp. is a biotechnology company
specializing in the discovery and development of immunotherapeutics aimed at
the treatment and eradication of cancer, and therapies for infectious
diseases, autoimmune disorders and transplant tissue rejection.
SAFE HARBOR STATEMENT
THIS NEWS RELEASE MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE
MEANING OF SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS
AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES AND EXCHANGE ACT OF
1934, AS AMENDED, WITH RESPECT TO ACHIEVING CORPORATE OBJECTIVES, DEVELOPING
ADDITIONAL PROJECT INTERESTS, THE COMPANY'S ANALYSIS OF OPPORTUNITIES IN THE
ACQUISITION AND DEVELOPMENT OF VARIOUS PROJECT INTERESTS AND CERTAIN OTHER
MATTERS. THESE STATEMENTS ARE MADE UNDER THE "SAFE HARBOR" PROVISIONS OF THE
UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 AND INVOLVE
RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY
FROM THOSE IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN."
SOURCE GeneMax Corp.
CONTACT: in North America, Marcus Johnson, +1-866-872-0077 or
+1-360-332-7734, or fax, +1-360-332-1643, or in Europe,
Richard Elliot-Square, 41-43-888-67-00, or fax, 41-43-888-67-09, both of
GeneMax Corp.
NEWS: October 30, 2003 09:45 AM US Eastern Timezone
CytoGenix Announces a Research Collaboration Agreement with Albert Einstein College of Medicine for Pre-Clinical Testing of a Gene Silencing Agent for Melanoma Cells
HOUSTON--(BUSINESS WIRE)--Oct. 30, 2003--CytoGenix Inc. (OTCBB:CYGX) announced Thursday that it has entered into an agreement with the Albert Einstein College of Medicine, Department of Oncology for studies using the Company's proprietary gene silencing DNA technology against a gene that is expressed in melanoma cells that produces a protein known to counteract the effect of several chemotherapeutic agents in difficult to treat cancers.
These studies will be conducted in the laboratory of Dr. Cy Stein, professor of medicine, urology and molecular pharmacology. Dr. Stein is an outside Director of the Company and a member of its Scientific Advisory Board. Dr. Lyuba Berimetskaya, assistant professor of medicine will lead the investigation.
"As an Oncologist, I am keenly aware of the need for effective cancer therapies. This is why for the past fifteen years we have concentrated our research efforts on gene therapy," stated Dr. Stein. "We believe that the CytoGenix ssDNA technology has significant scientific merit and should be extensively tested for its potential use in the clinic as an effective cancer therapeutic agent," adds Dr. Stein.
"Our Company is heavily science driven and relations with scientists like Cy Stein and his colleagues tend to keep us focused on the important scientific issues related to successful product development," states Dr. Malcolm Skolnick, CytoGenix chairman and CEO.
CytoGenix Inc. is a biopharmaceutical company that develops and markets innovative products and services based on its proprietary DNA expression technology. CytoGenix has products in pre-clinical development including, anti-herpes, anti-psoriasis and anti-inflammatory topical creams. The company owns a U.S. patent for its core DNA expression technology and has 40 international or U.S. pending patent applications.
SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology is found on the Web site at www.cytogenix
chipped, I hope so I had to unload today, been a bad week for some reason takin a blood bath had to take whatever green I could get,hehehe. You ever have one of those weeks when your about 30 to 45 seconds behind the eight ball, computer froze,level two went down and a bunch of partial fills. BLACK CLOUD OVER NJ I THINK.
Chipped, nice call on MEDE, thanks.eom
Buzz, thanks for yet another great pick (eag) eom.
The Only bad thing about this board:
"THE TAX MAN COMETH"
LOL....